Get the Stockscreener App
14.90
0.33%
-0.05
Mink Therapeutics Inc stock is traded at $14.90, with a volume of 38,436.
It is down -0.33% in the last 24 hours and down -29.22% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$14.95
Open:
$14.95
24h Volume:
38,436
Relative Volume:
0.04
Market Cap:
$59.39M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-20.41
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-0.07%
1M Performance:
-29.22%
6M Performance:
+47.52%
1Y Performance:
+84.47%
1-Day Range:
$14.76
$15.63
1-Week Range:
$13.90
$15.63
52-Week Range:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
14.90 | 58.27M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
MiNK Therapeutics Cuts Q2 Cash Use 31% - AOL.com
Resistance Break Could Fuel MiNK Therapeutics Inc. Rally2025 Dividend Review & Safe Investment Capital Preservation Plans - newsimpact.co.kr
MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - MSN
Using portfolio simulators with MiNK Therapeutics Inc. included2025 Big Picture & Long-Term Growth Stock Strategies - Newser
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy Rating with $35 Price Target - AInvest
MiNK Therapeutics Upgraded to Buy by H.C. Wainwright Amid Upcoming Catalysts - AInvest
MiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnerships - MSN
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript - MSN
What momentum shifts mean for MiNK Therapeutics Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
MiNK Therapeutics: Strategic Momentum and Capital Raise Potential in a High-Stakes Biotech Landscape - AInvest
How to build a dashboard for MiNK Therapeutics Inc. stockQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - Newser
What institutional flow reveals about MiNK Therapeutics Inc.July 2025 Market Mood & Accurate Intraday Trade Tips - Newser
MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year - MSN
MiNK Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
MiNK Therapeutics shares rise 10.31% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics shares rise 8.77% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating - TipRanks
HC Wainwright Upgrades MiNK Therapeutics to Buy From Neutral - MarketScreener
MiNK Therapeutics upgraded to Buy from Neutral by HC Wainwright & Co., PT raised to $35. - AInvest
MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results - Investing.com Canada
MiNK Therapeutics Inc (INKT) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q2 2025 Milestones and Financials - TipRanks
What high frequency data says about MiNK Therapeutics Inc.Trade Analysis Report & Community Consensus Trade Alerts - Newser
MiNK Therapeutics Inc. Recovery Likely Here’s What Data Shows2025 Breakouts & Breakdowns & Free Technical Pattern Based Buy Signals - beatles.ru
Real time alert setup for MiNK Therapeutics Inc. performanceJuly 2025 Drop Watch & Accurate Buy Signal Alerts - Newser
MiNK Therapeutics (INKT) and the Strategic Value of AGENT-797 in Oncology and Immune-Mediated Diseases - AInvest
MiNK Therapeutics Q2 2025: Unraveling Key Contradictions in GvHD and ARDS Trial Strategies - AInvest
MiNK Therapeutics Extends Cash Runway - Nasdaq
MiNK INKT Q2 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss - Investing.com Nigeria
Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss By Investing.com - Investing.com South Africa
Transcript : MiNK Therapeutics, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
MiNK Therapeutics Cuts Q2 Cash Use 31% - The Motley Fool
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - GlobeNewswire
Key resistance and support levels for MiNK Therapeutics Inc.Portfolio Gains Summary & Breakout Confirmation Alerts - Newser
Relative strength of MiNK Therapeutics Inc. in sector analysisFree Daily Chart Pattern Stock Forecast - Newser
Should I invest in MiNK Therapeutics Inc. before earningsSmart Portfolio Allocation - mustnews.co.kr
Mink Therapeutics Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
What makes MiNK Therapeutics Inc. stock price move sharplyFree Expert Verified Stock Trade Ideas - Newser
MiNK Therapeutics INKT 2025Q2 Earnings Preview Downside Concerns Amid Lack of Revenue and Profitability - AInvest
Using Python tools to backtest MiNK Therapeutics Inc. strategiesSafe Entry Strategy with High Win Rate - Newser
Candlestick Reversal Detected on MiNK Therapeutics Inc.’s ChartCapital Growth Entry Forecast Summary - beatles.ru
Is MiNK Therapeutics Inc. the Top Chart Pick This WeekInvestment Playbook for Growing Markets Shared - beatles.ru
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - Defense World
How does MiNK Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results - Jammu Links News
Should I hold or sell MiNK Therapeutics Inc. stock in 2025High-yield capital appreciation - Jammu Links News
How volatile is MiNK Therapeutics Inc. stock compared to the marketAchieve rapid portfolio appreciation - Jammu Links News
Why is MiNK Therapeutics Inc. stock attracting strong analyst attentionTrack stocks with high upside potential easily - Jammu Links News
What are analysts’ price targets for MiNK Therapeutics Inc. in the next 12 monthsUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for MiNK Therapeutics Inc.Consistently exceptional gains - Jammu Links News
Is it the right time to buy MiNK Therapeutics Inc. stockFree Stock Market Trend Analysis - Jammu Links News
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):